or Try an Advanced Search...

    Technical Analysis for RGLS - Regulus Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 1.90 6.44% 0.12
    RGLS closed up 6.44 percent on Monday, July 1, 2024, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical RGLS trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Support Bullish 6.44%
    Volume Surge Other 6.44%
    Lower Bollinger Band Walk Weakness 6.44%
    Stochastic Reached Oversold Weakness 6.44%
    Older End-of-Day Signals for RGLS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    200 DMA Support about 10 hours ago
    200 DMA Resistance about 11 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RGLS Chart by TradingView
    Basic chart:

    Profile

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Oligonucleotide Hepatocellular Carcinoma RNA Regulus Therapeutics Nucleic Acids Alnylam Pharmaceuticals Atherosclerosis Hepatitis C Virus Infection Nucleotides

    Is RGLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 What's Going On With Regulus Therapeutics Stock Monday?
    Jun 24 Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Jun 14 Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
    Jun 4 Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
    May 16 Regulus Therapeutics names Rekha Garg as chief medical officer
    May 16 Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
    May 9 Regulus Therapeutics GAAP EPS of -$0.29
    May 9 Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
    May 7 The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
    May 6 Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    See more RGLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.79
    52 Week Low 1.08
    Average Volume 930,080
    200-Day Moving Average 1.74
    50-Day Moving Average 2.23
    20-Day Moving Average 2.26
    10-Day Moving Average 2.18
    Average True Range 0.22
    RSI (14) 39.02
    ADX 24.87
    +DI 13.41
    -DI 29.10
    Chandelier Exit (Long, 3 ATRs) 1.96
    Chandelier Exit (Short, 3 ATRs) 2.33
    Upper Bollinger Bands 2.68
    Lower Bollinger Band 1.84
    Percent B (%b) 0.07
    BandWidth 36.90
    MACD Line -0.07
    MACD Signal Line -0.01
    MACD Histogram -0.0626
    Fundamentals Value
    Market Cap 38.42 Million
    Num Shares 20.2 Million
    EPS -1.59
    Price-to-Earnings (P/E) Ratio -1.19
    Price-to-Sales 7.43
    Price-to-Book 1.12
    PEG Ratio -0.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.17
    Resistance 3 (R3) 2.14 2.02 2.13
    Resistance 2 (R2) 2.02 1.95 2.04 2.11
    Resistance 1 (R1) 1.96 1.91 1.99 1.99 2.09
    Pivot Point 1.84 1.84 1.86 1.86 1.84
    Support 1 (S1) 1.78 1.77 1.81 1.81 1.71
    Support 2 (S2) 1.66 1.73 1.68 1.69
    Support 3 (S3) 1.60 1.66 1.68
    Support 4 (S4) 1.63